Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Stem Neoplasms | 33 | 2023 | 191 | 8.350 |
Why?
|
Glioma | 39 | 2024 | 3532 | 3.350 |
Why?
|
Pons | 10 | 2017 | 242 | 2.620 |
Why?
|
Central Nervous System Neoplasms | 10 | 2022 | 930 | 2.140 |
Why?
|
Endpoint Determination | 3 | 2020 | 594 | 1.700 |
Why?
|
Macaca mulatta | 16 | 2020 | 2365 | 1.620 |
Why?
|
Brain Neoplasms | 26 | 2024 | 9213 | 1.390 |
Why?
|
Antineoplastic Agents | 17 | 2023 | 13699 | 1.170 |
Why?
|
Medulloblastoma | 5 | 2022 | 683 | 1.080 |
Why?
|
Cerebrospinal Fluid | 2 | 2020 | 545 | 0.960 |
Why?
|
Dacarbazine | 6 | 2017 | 559 | 0.930 |
Why?
|
Blood-Brain Barrier | 6 | 2020 | 1036 | 0.930 |
Why?
|
Astrocytoma | 3 | 2023 | 780 | 0.900 |
Why?
|
Posterior Leukoencephalopathy Syndrome | 1 | 2023 | 50 | 0.850 |
Why?
|
Magnetic Resonance Spectroscopy | 6 | 2018 | 3782 | 0.770 |
Why?
|
Angiogenesis Inhibitors | 3 | 2020 | 2059 | 0.760 |
Why?
|
Models, Animal | 4 | 2016 | 2123 | 0.730 |
Why?
|
Thalidomide | 2 | 2020 | 886 | 0.730 |
Why?
|
Inulin | 1 | 2020 | 67 | 0.720 |
Why?
|
Cerebellar Neoplasms | 4 | 2022 | 591 | 0.710 |
Why?
|
Receptor, Macrophage Colony-Stimulating Factor | 1 | 2020 | 94 | 0.690 |
Why?
|
Child | 67 | 2024 | 80969 | 0.680 |
Why?
|
Neutropenia | 2 | 2023 | 893 | 0.640 |
Why?
|
Public Health Practice | 2 | 2018 | 221 | 0.620 |
Why?
|
Baltimore | 6 | 2018 | 234 | 0.610 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2018 | 43 | 0.610 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2018 | 330 | 0.600 |
Why?
|
Phosphorylcholine | 2 | 2017 | 153 | 0.600 |
Why?
|
Magnetic Resonance Imaging | 25 | 2023 | 36861 | 0.570 |
Why?
|
Designer Drugs | 1 | 2017 | 21 | 0.570 |
Why?
|
Child, Preschool | 42 | 2024 | 42684 | 0.560 |
Why?
|
Interinstitutional Relations | 1 | 2018 | 236 | 0.550 |
Why?
|
Bradykinin | 5 | 2006 | 205 | 0.550 |
Why?
|
Thrombocytopenia | 2 | 2023 | 1181 | 0.530 |
Why?
|
Aminopyridines | 1 | 2020 | 580 | 0.520 |
Why?
|
Carboplatin | 6 | 2011 | 799 | 0.510 |
Why?
|
Pyrroles | 3 | 2022 | 1126 | 0.500 |
Why?
|
Measles | 1 | 2017 | 181 | 0.490 |
Why?
|
Choline | 3 | 2012 | 522 | 0.480 |
Why?
|
Cannabinoids | 1 | 2017 | 175 | 0.470 |
Why?
|
Aspartic Acid | 3 | 2012 | 577 | 0.460 |
Why?
|
Alcoholic Beverages | 1 | 2016 | 266 | 0.460 |
Why?
|
Catheters, Indwelling | 2 | 2016 | 436 | 0.440 |
Why?
|
Neoplasms, Nerve Tissue | 1 | 2013 | 20 | 0.440 |
Why?
|
Tumor Burden | 5 | 2022 | 1913 | 0.440 |
Why?
|
Alcohol-Related Disorders | 1 | 2016 | 243 | 0.430 |
Why?
|
Microdialysis | 1 | 2013 | 163 | 0.430 |
Why?
|
Guanine | 3 | 2011 | 280 | 0.420 |
Why?
|
Catheterization | 2 | 2016 | 1431 | 0.420 |
Why?
|
Adolescent | 43 | 2024 | 89247 | 0.400 |
Why?
|
Brain Stem | 4 | 2017 | 862 | 0.390 |
Why?
|
Meningeal Neoplasms | 2 | 2018 | 1258 | 0.390 |
Why?
|
Pharmaceutical Preparations | 1 | 2019 | 1088 | 0.380 |
Why?
|
Area Under Curve | 7 | 2018 | 1645 | 0.360 |
Why?
|
Comparative Genomic Hybridization | 1 | 2011 | 474 | 0.350 |
Why?
|
Specimen Handling | 1 | 2015 | 708 | 0.340 |
Why?
|
Bayes Theorem | 1 | 2018 | 2357 | 0.340 |
Why?
|
Hydroxamic Acids | 2 | 2015 | 483 | 0.340 |
Why?
|
Protons | 3 | 2011 | 1113 | 0.330 |
Why?
|
Ethanol | 1 | 2016 | 1332 | 0.330 |
Why?
|
Maximum Tolerated Dose | 5 | 2020 | 899 | 0.320 |
Why?
|
Age of Onset | 3 | 2020 | 3346 | 0.310 |
Why?
|
Humans | 95 | 2024 | 768887 | 0.310 |
Why?
|
Standard of Care | 1 | 2013 | 570 | 0.310 |
Why?
|
Ependymoma | 3 | 2022 | 328 | 0.310 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2009 | 137 | 0.310 |
Why?
|
Male | 57 | 2024 | 365249 | 0.310 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2020 | 2831 | 0.300 |
Why?
|
Supratentorial Neoplasms | 1 | 2009 | 159 | 0.300 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2020 | 10778 | 0.290 |
Why?
|
Interferon-alpha | 1 | 2011 | 910 | 0.280 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2023 | 11886 | 0.280 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2017 | 2460 | 0.280 |
Why?
|
Tissue Distribution | 3 | 2020 | 2299 | 0.270 |
Why?
|
Consensus | 4 | 2020 | 3214 | 0.270 |
Why?
|
Metabolic Clearance Rate | 3 | 2018 | 363 | 0.260 |
Why?
|
Polyethylene Glycols | 1 | 2011 | 1197 | 0.260 |
Why?
|
Administration, Intranasal | 2 | 2018 | 485 | 0.260 |
Why?
|
Public Health | 2 | 2016 | 2680 | 0.250 |
Why?
|
Molecular Imaging | 1 | 2012 | 826 | 0.250 |
Why?
|
Chromosome Aberrations | 1 | 2011 | 1780 | 0.240 |
Why?
|
Infusions, Intravenous | 7 | 2015 | 2231 | 0.240 |
Why?
|
Health Promotion | 1 | 2017 | 2210 | 0.240 |
Why?
|
Animals | 27 | 2023 | 169408 | 0.240 |
Why?
|
Half-Life | 4 | 2018 | 651 | 0.230 |
Why?
|
Neoplasms | 8 | 2019 | 22390 | 0.230 |
Why?
|
Time Factors | 10 | 2020 | 40266 | 0.230 |
Why?
|
Positron-Emission Tomography | 5 | 2022 | 6673 | 0.220 |
Why?
|
Radiation Tolerance | 2 | 2017 | 478 | 0.220 |
Why?
|
Neurotoxicity Syndromes | 1 | 2008 | 302 | 0.220 |
Why?
|
Diffusion Tensor Imaging | 1 | 2014 | 2426 | 0.220 |
Why?
|
Osteosarcoma | 1 | 2009 | 911 | 0.220 |
Why?
|
Opioid-Related Disorders | 1 | 2018 | 2189 | 0.210 |
Why?
|
Doxorubicin | 2 | 2000 | 2234 | 0.210 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 15471 | 0.210 |
Why?
|
Infant | 17 | 2018 | 36541 | 0.210 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2022 | 2056 | 0.210 |
Why?
|
Drug Administration Schedule | 6 | 2013 | 4862 | 0.200 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2007 | 778 | 0.200 |
Why?
|
Research Design | 1 | 2018 | 6213 | 0.200 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 5707 | 0.200 |
Why?
|
Organoplatinum Compounds | 2 | 2015 | 408 | 0.190 |
Why?
|
Neoplasms, Second Primary | 1 | 2009 | 1060 | 0.190 |
Why?
|
Gangliosides | 1 | 2022 | 132 | 0.190 |
Why?
|
Prognosis | 10 | 2024 | 30044 | 0.190 |
Why?
|
Female | 41 | 2024 | 397464 | 0.180 |
Why?
|
Exotoxins | 2 | 2018 | 123 | 0.180 |
Why?
|
Intracranial Pressure | 1 | 2023 | 325 | 0.180 |
Why?
|
Stroke | 1 | 2023 | 9756 | 0.180 |
Why?
|
Young Adult | 18 | 2024 | 60110 | 0.180 |
Why?
|
Substance-Related Disorders | 1 | 2017 | 4429 | 0.180 |
Why?
|
Clinical Trials as Topic | 2 | 2013 | 8055 | 0.170 |
Why?
|
Craniopharyngioma | 1 | 2023 | 279 | 0.170 |
Why?
|
Brain | 5 | 2023 | 27476 | 0.170 |
Why?
|
Rhabdoid Tumor | 1 | 2022 | 211 | 0.170 |
Why?
|
Immunotherapy, Adoptive | 2 | 2022 | 1519 | 0.170 |
Why?
|
Nasal Mucosa | 1 | 2023 | 416 | 0.170 |
Why?
|
Fluconazole | 1 | 2000 | 156 | 0.160 |
Why?
|
Biological Availability | 1 | 2020 | 392 | 0.160 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2017 | 349 | 0.160 |
Why?
|
Interleukin-13 | 2 | 2018 | 391 | 0.160 |
Why?
|
Survival Rate | 6 | 2024 | 12873 | 0.160 |
Why?
|
Infusions, Intraventricular | 1 | 2018 | 31 | 0.160 |
Why?
|
Histones | 2 | 2022 | 2603 | 0.160 |
Why?
|
Perfusion Imaging | 1 | 2020 | 196 | 0.160 |
Why?
|
Carcinoma, Medullary | 1 | 1999 | 116 | 0.150 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2024 | 958 | 0.150 |
Why?
|
Sickle Cell Trait | 1 | 1999 | 86 | 0.150 |
Why?
|
Creatine | 2 | 2012 | 427 | 0.150 |
Why?
|
Smith-Lemli-Opitz Syndrome | 1 | 2017 | 46 | 0.150 |
Why?
|
Local Government | 1 | 2018 | 83 | 0.150 |
Why?
|
Neoplasm Seeding | 1 | 2018 | 85 | 0.150 |
Why?
|
Hematuria | 1 | 1999 | 233 | 0.140 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 493 | 0.140 |
Why?
|
Neurofibromatosis 1 | 2 | 2017 | 561 | 0.140 |
Why?
|
Organizational Case Studies | 1 | 2018 | 301 | 0.140 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1893 | 0.140 |
Why?
|
Drug Labeling | 1 | 2019 | 250 | 0.140 |
Why?
|
Measles Vaccine | 1 | 2017 | 80 | 0.140 |
Why?
|
Cyclosporine | 1 | 2000 | 777 | 0.140 |
Why?
|
Cerebral Cortex | 1 | 2013 | 5834 | 0.140 |
Why?
|
Bone Neoplasms | 1 | 2009 | 2565 | 0.140 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 3724 | 0.140 |
Why?
|
Administration, Oral | 3 | 2015 | 4042 | 0.140 |
Why?
|
Immunomodulation | 1 | 2020 | 549 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 4 | 2018 | 6546 | 0.130 |
Why?
|
Registries | 5 | 2022 | 8384 | 0.130 |
Why?
|
Benzoxazoles | 1 | 2017 | 92 | 0.130 |
Why?
|
Civil Disorders | 1 | 2015 | 8 | 0.130 |
Why?
|
Treatment Outcome | 10 | 2023 | 65485 | 0.130 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2000 | 682 | 0.130 |
Why?
|
Powders | 1 | 2016 | 79 | 0.130 |
Why?
|
Public Health Administration | 1 | 2018 | 242 | 0.130 |
Why?
|
Drug Evaluation, Preclinical | 2 | 2019 | 1339 | 0.120 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2022 | 957 | 0.120 |
Why?
|
Social Problems | 1 | 2015 | 108 | 0.120 |
Why?
|
Antifungal Agents | 1 | 2000 | 761 | 0.120 |
Why?
|
Pathology, Molecular | 1 | 2018 | 329 | 0.120 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2018 | 794 | 0.120 |
Why?
|
Valproic Acid | 1 | 2017 | 444 | 0.110 |
Why?
|
Pituitary Neoplasms | 1 | 2023 | 1326 | 0.110 |
Why?
|
Autopsy | 2 | 2016 | 1013 | 0.110 |
Why?
|
Civil Defense | 1 | 2015 | 115 | 0.110 |
Why?
|
Injections, Intravenous | 3 | 2013 | 1379 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2020 | 965 | 0.110 |
Why?
|
Lateral Ventricles | 1 | 2015 | 145 | 0.110 |
Why?
|
High-Throughput Screening Assays | 1 | 2019 | 941 | 0.110 |
Why?
|
Brain Edema | 1 | 2018 | 607 | 0.110 |
Why?
|
Pyrimidines | 2 | 2017 | 3050 | 0.110 |
Why?
|
5-Methylcytosine | 1 | 2014 | 147 | 0.110 |
Why?
|
Mutation | 4 | 2024 | 30266 | 0.110 |
Why?
|
Police | 1 | 2015 | 158 | 0.110 |
Why?
|
SEER Program | 1 | 2018 | 1473 | 0.110 |
Why?
|
Vincristine | 1 | 2015 | 1040 | 0.110 |
Why?
|
Cytosine | 1 | 2014 | 213 | 0.110 |
Why?
|
Benzazepines | 1 | 2015 | 309 | 0.110 |
Why?
|
State Government | 1 | 2016 | 389 | 0.100 |
Why?
|
Adult | 21 | 2024 | 223818 | 0.100 |
Why?
|
Recombinant Fusion Proteins | 2 | 2018 | 3744 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2022 | 2063 | 0.100 |
Why?
|
Poultry Diseases | 1 | 2012 | 24 | 0.100 |
Why?
|
DNA, Neoplasm | 2 | 2022 | 1748 | 0.100 |
Why?
|
Salmonella Infections, Animal | 1 | 2012 | 60 | 0.100 |
Why?
|
Community Health Services | 1 | 2017 | 659 | 0.100 |
Why?
|
Fourth Ventricle | 1 | 2012 | 32 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2015 | 622 | 0.100 |
Why?
|
Indoles | 2 | 2022 | 1836 | 0.100 |
Why?
|
Clinical Protocols | 1 | 2017 | 1445 | 0.100 |
Why?
|
Prospective Studies | 7 | 2022 | 54950 | 0.090 |
Why?
|
Cholesterol | 2 | 2017 | 2913 | 0.090 |
Why?
|
Attitude to Death | 1 | 2014 | 401 | 0.090 |
Why?
|
United States Food and Drug Administration | 1 | 2019 | 1672 | 0.090 |
Why?
|
Drug Carriers | 1 | 2015 | 710 | 0.090 |
Why?
|
Zoonoses | 1 | 2012 | 180 | 0.090 |
Why?
|
Basilar Artery | 1 | 2012 | 207 | 0.090 |
Why?
|
DNA Modification Methylases | 1 | 2011 | 210 | 0.090 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2433 | 0.090 |
Why?
|
Health Education | 1 | 2017 | 1059 | 0.090 |
Why?
|
Salmonella Infections | 1 | 2012 | 172 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2016 | 8664 | 0.090 |
Why?
|
Paraffin Embedding | 1 | 2011 | 306 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 618 | 0.090 |
Why?
|
International Cooperation | 1 | 2017 | 1436 | 0.090 |
Why?
|
Drug Prescriptions | 1 | 2019 | 1673 | 0.090 |
Why?
|
Bereavement | 1 | 2014 | 310 | 0.090 |
Why?
|
Disease Outbreaks | 2 | 2017 | 1761 | 0.090 |
Why?
|
Statistics, Nonparametric | 2 | 2014 | 2862 | 0.090 |
Why?
|
Camptothecin | 1 | 2013 | 600 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2024 | 39394 | 0.080 |
Why?
|
Neurology | 1 | 2018 | 787 | 0.080 |
Why?
|
DNA Repair Enzymes | 1 | 2011 | 346 | 0.080 |
Why?
|
Organs at Risk | 1 | 2012 | 368 | 0.080 |
Why?
|
Pilot Projects | 2 | 2019 | 8742 | 0.080 |
Why?
|
Ki-67 Antigen | 1 | 2011 | 628 | 0.080 |
Why?
|
Disaster Planning | 1 | 2015 | 559 | 0.080 |
Why?
|
Age Factors | 6 | 2024 | 18454 | 0.080 |
Why?
|
Infant, Newborn | 7 | 2022 | 26394 | 0.080 |
Why?
|
Benzimidazoles | 1 | 2014 | 864 | 0.080 |
Why?
|
United States | 7 | 2019 | 73180 | 0.080 |
Why?
|
Longitudinal Studies | 3 | 2022 | 14795 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2019 | 3621 | 0.080 |
Why?
|
Epigenomics | 1 | 2014 | 961 | 0.080 |
Why?
|
Constriction, Pathologic | 1 | 2012 | 1104 | 0.080 |
Why?
|
Radiopharmaceuticals | 2 | 2022 | 2734 | 0.070 |
Why?
|
Imaging, Three-Dimensional | 1 | 2001 | 4077 | 0.070 |
Why?
|
Proportional Hazards Models | 2 | 2013 | 12563 | 0.070 |
Why?
|
Informed Consent | 1 | 2014 | 1010 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2606 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2011 | 6320 | 0.070 |
Why?
|
Disease-Free Survival | 2 | 2011 | 6856 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2597 | 0.070 |
Why?
|
Gaucher Disease | 1 | 2007 | 110 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2013 | 9442 | 0.070 |
Why?
|
Lumbar Vertebrae | 1 | 2016 | 1889 | 0.070 |
Why?
|
Maternal Behavior | 1 | 2008 | 309 | 0.060 |
Why?
|
Combined Modality Therapy | 4 | 2011 | 8559 | 0.060 |
Why?
|
Health Policy | 1 | 2018 | 2700 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2830 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2008 | 640 | 0.060 |
Why?
|
Hydrocephalus | 1 | 2012 | 770 | 0.060 |
Why?
|
Hematologic Diseases | 1 | 2009 | 498 | 0.060 |
Why?
|
Epigenesis, Genetic | 1 | 2018 | 3836 | 0.060 |
Why?
|
Computer Simulation | 1 | 2018 | 6289 | 0.060 |
Why?
|
Mice, Inbred C57BL | 1 | 2023 | 22381 | 0.060 |
Why?
|
Immunohistochemistry | 2 | 2013 | 11119 | 0.060 |
Why?
|
Mother-Child Relations | 1 | 2008 | 500 | 0.060 |
Why?
|
Neurofibroma, Plexiform | 1 | 2004 | 66 | 0.060 |
Why?
|
Models, Statistical | 1 | 2018 | 5107 | 0.050 |
Why?
|
Drug Synergism | 2 | 2019 | 1762 | 0.050 |
Why?
|
Biopsy | 2 | 2013 | 6805 | 0.050 |
Why?
|
Disease Models, Animal | 3 | 2018 | 18366 | 0.050 |
Why?
|
Quality of Life | 4 | 2023 | 13510 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2012 | 5323 | 0.050 |
Why?
|
Contrast Media | 2 | 2014 | 5334 | 0.050 |
Why?
|
Mice | 4 | 2023 | 82074 | 0.050 |
Why?
|
Disease Progression | 3 | 2018 | 13677 | 0.050 |
Why?
|
Perfusion | 1 | 2007 | 1402 | 0.050 |
Why?
|
Tissue Array Analysis | 2 | 2014 | 551 | 0.050 |
Why?
|
Drug Delivery Systems | 1 | 2013 | 2238 | 0.050 |
Why?
|
Observer Variation | 1 | 2008 | 2623 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 1999 | 4300 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2011 | 6512 | 0.050 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2009 | 1539 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2022 | 9081 | 0.050 |
Why?
|
Man-Machine Systems | 1 | 2001 | 42 | 0.050 |
Why?
|
Flushing | 1 | 2001 | 52 | 0.050 |
Why?
|
Primary Health Care | 1 | 2018 | 4748 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2813 | 0.050 |
Why?
|
Pyrimidine Nucleosides | 1 | 2000 | 7 | 0.050 |
Why?
|
Schizophrenic Psychology | 1 | 2008 | 1651 | 0.050 |
Why?
|
Drug Interactions | 2 | 2009 | 1421 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2024 | 81892 | 0.040 |
Why?
|
Adaptation, Psychological | 1 | 2011 | 2667 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5520 | 0.040 |
Why?
|
Family | 1 | 2011 | 3208 | 0.040 |
Why?
|
Parents | 1 | 2014 | 3597 | 0.040 |
Why?
|
Cerebral Hemorrhage | 1 | 2012 | 2660 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7460 | 0.040 |
Why?
|
Spinal Cord Neoplasms | 1 | 2022 | 263 | 0.040 |
Why?
|
Sequence Analysis, RNA | 2 | 2019 | 2041 | 0.040 |
Why?
|
Surgery, Computer-Assisted | 1 | 2007 | 1006 | 0.040 |
Why?
|
Infusions, Intralesional | 1 | 2018 | 3 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2012 | 3411 | 0.040 |
Why?
|
Caregivers | 1 | 2011 | 2308 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2019 | 20244 | 0.040 |
Why?
|
Algorithms | 2 | 2018 | 14199 | 0.040 |
Why?
|
Alkaloids | 1 | 2000 | 192 | 0.040 |
Why?
|
Pseudomonas | 1 | 2018 | 124 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2018 | 7956 | 0.040 |
Why?
|
Recurrence | 1 | 2010 | 8512 | 0.040 |
Why?
|
Injections, Intraventricular | 1 | 2018 | 227 | 0.040 |
Why?
|
Spectrometry, Fluorescence | 1 | 2000 | 694 | 0.040 |
Why?
|
Sulfonamides | 1 | 2007 | 1982 | 0.040 |
Why?
|
Gadolinium DTPA | 2 | 2014 | 823 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2019 | 17174 | 0.040 |
Why?
|
Lactones | 1 | 2019 | 316 | 0.040 |
Why?
|
Retreatment | 1 | 2018 | 600 | 0.030 |
Why?
|
Ribosomal Protein S6 Kinases | 1 | 2017 | 203 | 0.030 |
Why?
|
Choroid Plexus | 1 | 2000 | 250 | 0.030 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2018 | 195 | 0.030 |
Why?
|
Seizures | 2 | 2017 | 3000 | 0.030 |
Why?
|
Risk Assessment | 1 | 2018 | 24330 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14751 | 0.030 |
Why?
|
Monomeric GTP-Binding Proteins | 1 | 2017 | 199 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2013 | 10397 | 0.030 |
Why?
|
New Zealand | 1 | 2017 | 360 | 0.030 |
Why?
|
Amino Acids | 1 | 2022 | 1716 | 0.030 |
Why?
|
Class Ia Phosphatidylinositol 3-Kinase | 1 | 2016 | 77 | 0.030 |
Why?
|
Activin Receptors, Type I | 1 | 2016 | 134 | 0.030 |
Why?
|
Sphingomyelins | 1 | 2015 | 105 | 0.030 |
Why?
|
Hypotension | 1 | 2001 | 888 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2004 | 2228 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2000 | 1207 | 0.030 |
Why?
|
Cerebrum | 1 | 2016 | 132 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2008 | 7148 | 0.030 |
Why?
|
Basal Ganglia | 1 | 2017 | 555 | 0.030 |
Why?
|
Neoplasm Staging | 3 | 2018 | 11262 | 0.030 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2016 | 329 | 0.030 |
Why?
|
Convection | 1 | 2014 | 30 | 0.030 |
Why?
|
Cell Death | 1 | 2019 | 1682 | 0.030 |
Why?
|
Fatal Outcome | 1 | 1999 | 1836 | 0.030 |
Why?
|
Blood Vessels | 1 | 2000 | 1110 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 620 | 0.030 |
Why?
|
Stereotaxic Techniques | 1 | 2016 | 559 | 0.030 |
Why?
|
Headache | 1 | 2001 | 1263 | 0.030 |
Why?
|
Mitotic Index | 1 | 2013 | 162 | 0.030 |
Why?
|
Australia | 1 | 2017 | 1265 | 0.030 |
Why?
|
Lymphoma, B-Cell | 1 | 2000 | 945 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 1839 | 0.030 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2014 | 428 | 0.020 |
Why?
|
Poultry | 1 | 2012 | 79 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2015 | 969 | 0.020 |
Why?
|
Mice, SCID | 1 | 2017 | 2631 | 0.020 |
Why?
|
Liposomes | 1 | 2015 | 792 | 0.020 |
Why?
|
Salmonella | 1 | 2012 | 125 | 0.020 |
Why?
|
Serotyping | 1 | 2012 | 332 | 0.020 |
Why?
|
Canada | 1 | 2017 | 2129 | 0.020 |
Why?
|
Oncogene Proteins | 1 | 2015 | 718 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2015 | 2475 | 0.020 |
Why?
|
Death | 1 | 2015 | 683 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2017 | 1111 | 0.020 |
Why?
|
Catheters | 1 | 2014 | 427 | 0.020 |
Why?
|
Proteinuria | 1 | 2013 | 610 | 0.020 |
Why?
|
Central Nervous System | 1 | 2017 | 1345 | 0.020 |
Why?
|
Metabolomics | 1 | 2019 | 1675 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2008 | 5342 | 0.020 |
Why?
|
Radiotherapy Dosage | 2 | 2008 | 2920 | 0.020 |
Why?
|
Signal Transduction | 3 | 2017 | 23652 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2015 | 2108 | 0.020 |
Why?
|
Mice, Nude | 1 | 2015 | 3631 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3629 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 74971 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5035 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2000 | 3701 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2000 | 4428 | 0.020 |
Why?
|
Software | 1 | 2001 | 4480 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1855 | 0.020 |
Why?
|
Infant Behavior | 1 | 2008 | 157 | 0.020 |
Why?
|
Infant Care | 1 | 2008 | 182 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2884 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1557 | 0.020 |
Why?
|
Phosphorylation | 1 | 2017 | 8317 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2537 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2022 | 9549 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2019 | 7609 | 0.020 |
Why?
|
Equipment Design | 1 | 2014 | 3529 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9564 | 0.020 |
Why?
|
DNA Repair | 1 | 2015 | 2054 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2960 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3438 | 0.020 |
Why?
|
Cisplatin | 1 | 2011 | 1661 | 0.020 |
Why?
|
Cell Movement | 1 | 2017 | 5216 | 0.020 |
Why?
|
HIV Infections | 1 | 2011 | 17589 | 0.010 |
Why?
|
Intraoperative Care | 1 | 2007 | 771 | 0.010 |
Why?
|
Kidney | 1 | 1999 | 7057 | 0.010 |
Why?
|
Facial Paralysis | 1 | 2007 | 346 | 0.010 |
Why?
|
Cohort Studies | 1 | 2006 | 41800 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6242 | 0.010 |
Why?
|
Tandem Mass Spectrometry | 1 | 2009 | 1197 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2000 | 9264 | 0.010 |
Why?
|
Automation | 1 | 2004 | 589 | 0.010 |
Why?
|
Social Support | 1 | 2011 | 2193 | 0.010 |
Why?
|
Hemorrhage | 1 | 2013 | 3465 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26384 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2017 | 10486 | 0.010 |
Why?
|
Apoptosis | 1 | 2017 | 9528 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2015 | 5803 | 0.010 |
Why?
|
Idoxuridine | 1 | 2000 | 111 | 0.010 |
Why?
|
Brain Mapping | 1 | 2016 | 6740 | 0.010 |
Why?
|
Aldehyde Oxidoreductases | 1 | 2000 | 88 | 0.010 |
Why?
|
Incidence | 1 | 2018 | 21545 | 0.010 |
Why?
|
Ferrets | 1 | 2000 | 181 | 0.010 |
Why?
|
DNA Methylation | 1 | 2014 | 4432 | 0.010 |
Why?
|
Stem Cell Transplantation | 1 | 2008 | 1602 | 0.010 |
Why?
|
Hematologic Tests | 1 | 2000 | 239 | 0.010 |
Why?
|
Middle Aged | 3 | 2024 | 223740 | 0.010 |
Why?
|
Staurosporine | 1 | 2000 | 241 | 0.010 |
Why?
|
Patient Participation | 1 | 2008 | 1448 | 0.010 |
Why?
|
Urine | 1 | 2000 | 362 | 0.010 |
Why?
|
Radiotherapy | 1 | 2005 | 1506 | 0.010 |
Why?
|
Aged | 3 | 2024 | 171790 | 0.010 |
Why?
|
Prodrugs | 1 | 2000 | 275 | 0.010 |
Why?
|
Neurons | 1 | 2017 | 9524 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 2007 | 2736 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2007 | 2110 | 0.010 |
Why?
|
Stomach | 1 | 2000 | 702 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 1999 | 20776 | 0.010 |
Why?
|
Sex Factors | 1 | 2009 | 10641 | 0.010 |
Why?
|
Hypertension | 1 | 2013 | 8615 | 0.010 |
Why?
|
Bone Marrow | 1 | 2000 | 2935 | 0.010 |
Why?
|
Schizophrenia | 1 | 2008 | 6987 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2000 | 3473 | 0.000 |
Why?
|
DNA | 1 | 2000 | 7214 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2012 | 59738 | 0.000 |
Why?
|
B-Lymphocytes | 1 | 2000 | 4794 | 0.000 |
Why?
|
Liver | 1 | 2000 | 7579 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 2000 | 10276 | 0.000 |
Why?
|